TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03463200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional elastic tape tensioned
Description: Application of Kinesio Taping with tension in the erector spine muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional elastic tape non-tensioned
Description: Application of Kinesio Taping without tension in the erector spine muscles.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rigid Tape
Description: Application of Micropore tape in the erector spine muscles.
Study: NCT01302145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1941
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Tablet
Study: NCT00621504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil for Injection
Description: 2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ceftriaxone
Description: 1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
Study: NCT01302145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study: NCT00621504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
Study: NCT01577485

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics in an pastille
Description: Test group

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control pastille
Description: Control group
Study: NCT02013843

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community-based treatment of overweight and obesity
Description: Community based treatment of overweight and obese children using the Holbaek-method.
Study: NCT01935050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Cognitive-Behavioral Self-Help
Description: Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
Study: NCT01354483

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 30mg/kg i.v. methylprednisolone

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 30mg/kg i.v. methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium Carbonate Tablet
Description: 6 weeks
Study: NCT03590509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine Program
Description: A telemedicine platform (Zoom) will be added to comprehensive care (CC) to be used by the CC providers to make observations in the home to augment care, help address acute problems remotely at any hour, better coordinate care with healthcare personnel, and thereby reduce clinic visits, ED visits, and hospitalizations. Home visits\* will be conducted by a nurse home visitor whenever considered likely to be beneficial for any of the CMC and at least once by the assigned CC provider immediately following enrollment of children with chronic respiratory failure requiring mechanical ventilation at home.~\*After the approval of the study protocol, the home-visitation component of the integrated intervention was deemed not to be feasible with the available resources and personnel and has was not implemented

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Comprehensive Care
Description: Comprehensive care (CC) provided in an enhanced medical home to assure effective care at any hour for or children with medical complexity
Study: NCT00428649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 µg selenium
Description: 20 µg selenium as selenomethionine
Study: NCT00655174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluvoxamine
Description: Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
Study: NCT00428649

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 40 µg selenium
Description: 40 µg selenium as selenomethionine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 60 µg selenium
Description: 60 µg selenium as selenomethionine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 80 µg selenium
Description: 80 µg selenium as selenomethionine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 100 µg selenium
Description: 100 µg selenium as selenomethionine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 120 µg selenium
Description: 120 µg selenium as selenomethionine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00655174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
Study: NCT03711240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 5mg/kg iv day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 2-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 150mg/m2 1.5-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 2-hour iv infusion, day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
Study: NCT03094507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivicay
Description: 50 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivicay
Description: 50 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezolsta
Description: darunavir 800 mg/cobicistat 150 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezolsta
Description: darunavir 800 mg/cobicistat 150 mg once daily
Study: NCT03159312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity based on a moderate exercise program
Description: Physical exercise program begins with a 2-week adaptation stage, climbs onto the treadmill (HP Cosmos®). The programming of the tape will be done initially with an intensity of 40% of its FCdRes obtained from the formula of Karvonen after performing the 6-minute walk test, you will have to maintain that intensity for 15 min, the patient is evaluated with the Borg scale and oxygen saturation permanently.After two weeks of adaptation, the HRdRes becomes to be calculated, 59% of said frequency will be modified until the exercise program is completed.The training is 30 minutes in the tradmill machine.The work of muscle strengthening of biceps, triceps, deltoids and pectorals, will be progressive in intensity and number of repetitions, determined by the evaluation of 1 Rmax. The start of work with weights is 40% of the Rmax, it will be modified monthly from 40% to 75%. Cycloergometer training (Monark ®) is without load for 15 minutes.
Study: NCT00272038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 150mg QD
Study: NCT04590846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constipation Health Education Intervention Course
Description: The 4-weeks health education includes three dimensions. The first is Causes and Hazards of Constipation. The second is Constipation Symptoms and Criteria. The third is Constipation Treatment Strategies and Prevention.~Health education leaflets with 3 to 5 test questions in the weekly are distributed once a week, students will bring them back to parents, and parents need to complete the answers and sign after reading them.
Study: NCT06471881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Two mandibular implants
Description: Rehabilitation with two mandibular implants and a mandibular implant overdenture supported by a computer-aided design bar
Study: NCT03072693

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Home-based remote heart failure management
Description: For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Home-based physiological parameter recording only
Description: For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
Study: NCT00772629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular
Study: NCT03457675

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S DBS implant for OCD
Description: DBS system consists of the Activa PC+S Neurostimulation System:~Model 37604 Activa PC+S Neurostimulator Model 37087 DBS Extension Model 37441 Patient Programmer Model 8181 Sensing Programmer Model 8180 Sensing Programmer Software Nexus D2/D3 System Nexus D2/D3 Application Programming Interface (API) Dow Corning Medical Adhesive, Medtronic Part #080118 Model 3387/3389 DBS Leads Model 37022 External Neurostimulator Model 8840 N'Vision Clinician Programmer Model 8870 Application Card Model 37642 Patient Programmer Model 37092 Patient Programmer Antenna

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Month Blinded Discontinuation Period
Description: The subject and Independent Evaluators are blinded to timing of discontinuation. In all cases, the sequence will be as follows in one-week segments: 100% Active, 50% Active, Sham and Sham. Subjects will be seen weekly. Amplitude will be reduced by 50% at start of week 2 and turned off at start of week 3. Subjects will be told that DBS will be discontinued at some point during the 4 weeks. The purpose of the 50% initial reduction is to minimize rebound effects. The programmer (not the PI in this case) will be open to the design and perform sham activation as described previously. Relapse is defined as a 25% increase of the Y-BOCS over two consecutive visits compared to discontinuation baseline.
Study: NCT04590846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Course
Description: General courses about health issues according to the curriculum of each primary school.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Course
Description: General courses about health issues according to the curriculum of each primary school.
Study: NCT04525716

Intervention type: OTHER
Intervention: COVID-19 infection status
Description: We will compare patients with/without confirmed COVID-19 infection

Intervention type: OTHER
Intervention: COVID-19 infection status
Description: We will compare patients with/without confirmed COVID-19 infection
Study: NCT03879564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine in NSS (1 mg/ml) IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: NSS IV bolus 0.3 ml/kg then drip 0.09 ml/kg/hr
Study: NCT00552747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fenofibrate
Description: fenofibrate 160 mg capsules qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsules placebo
Study: NCT01587898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Tablet
Study: NCT02397928

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovoTTF-100L device
Description: Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
Study: NCT01587898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet
Study: NCT02080819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa 400/100 BID
Description: Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa/carbidopa 400/100 BID
Description: Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.~Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance.
Study: NCT02498171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine with fentanyl
Description: Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine with bupivacaine
Description: Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.~The fetus was monitored with an ultrasonic aided fetal Doppler until delivery
Study: NCT01788215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 200mg/day in divided doses of 100mg twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: 1 pill twice a day
Study: NCT02397928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
Study: NCT01897246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corrective osteotomy with computer-assisted pre-operative planning
Description: The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corrective osteotomy with conventional preoperative planning
Description: The corrective osteotomy will be planned with conventional preoperative planning.
Study: NCT00477126

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GPO ritonavir versus Norvir
Description: RTV generic compared to reference drugs (Norvir, Abbott)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GPO ritonavir versus Norvir
Description: RTV generic compared to reference drugs (Norvir, Abbott)
Study: NCT02405338

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WT1/PRAME vaccination
Study: NCT02871037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Single or repeated, escalating dose of PF-05221304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Single or repeated, escalating dose of PF-05221304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Single or repeated, escalating dose of PF-05221304
Study: NCT01960322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemetric
Description: A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
Study: NCT02549339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 43204 gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Study: NCT01014845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hepatitis E vaccine
Description: Intramuscularly given at 0, 1, 6m for three doses.
Study: NCT02871037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05221304
Description: Single or repeated, escalating dose of PF-05221304

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or repeated dose of placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single or repeated dose of placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single or repeated dose of placebo
Study: NCT02340871

Intervention type: GENETIC
Intervention: Genetic testing
Description: Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
Study: NCT02527772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin+Gemcitabine
Description: Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX4
Description: Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
Study: NCT00612105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retigabine
Description: 150mg/day up to 900mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study: NCT03228329

Intervention type: OTHER
Group type: OTHER
Intervention: fluid boluses
Description: fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
Study: NCT01651962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbutaline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl